Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Change in Accured Expenses (2017 - 2026)

Cogent Biosciences' Change in Accured Expenses history spans 10 years, with the latest figure at $29000.0 for Q1 2026.

  • Quarterly Change in Accured Expenses rose 480.0% to $29000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Mar 2026, up 59.26% year-over-year, with the annual reading at $10.7 million for FY2025, N/A changed from the prior year.
  • Change in Accured Expenses came in at $29000.0 for Q1 2026, down from $9.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $10.1 million in Q2 2024 to a low of -$10.3 million in Q4 2024.
  • The 5-year median for Change in Accured Expenses is $2.6 million (2022), against an average of $1.7 million.
  • Year-over-year, Change in Accured Expenses plummeted 1384.92% in 2023 and then soared 480.0% in 2026.
  • Cogent Biosciences' Change in Accured Expenses stood at $3.8 million in 2022, then tumbled by 30.93% to $2.6 million in 2023, then crashed by 491.74% to -$10.3 million in 2024, then surged by 188.39% to $9.1 million in 2025, then crashed by 99.68% to $29000.0 in 2026.
  • Per Business Quant, the three most recent readings for COGT's Change in Accured Expenses are $29000.0 (Q1 2026), $9.1 million (Q4 2025), and $4.6 million (Q3 2025).